Roche Reports Results of Gazyva (obinutuzumab) in P-II NOBILITY Study for Lupus Nephritis

 Roche Reports Results of Gazyva (obinutuzumab) in P-II NOBILITY Study for Lupus Nephritis

Roche Reports Results of Gazyva (obinutuzumab) in P-II NOBILITY Study for Lupus Nephritis

Shots:

  • The P-II NOBILITY study involves assessing of Gazyva + mycophenolate mofetil/ mycophenolic acid and corticosteroids vs PBO + MMF/MPA and corticosteroids in 125 patients with ISN/RPS 2003 class III or IV proliferative lupus nephritis
  • The P-II NOBILITY study results:  met its 1EPs & 2EPs, CRR @52-76 wks. (40% vs 18%); improvement in overall renal response and serologic markers of disease activity; @76wks. SAEs (24% vs 29%); serious infection (6% vs 18%)
  • Gazyva is mAb targeting CD20, act by attacking targeted cells both directly and together with the body’s immune system and has received FDA’s BT designation in Sept’19

Click here to­ read full press release/ article | Ref: Roche  | Image: Pharmacy Guide

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post